



DEPARTMENT OF HEALTH & HUMAN SERVICES

Public Health Service

Food and Drug Administration  
DOCUMENT CONTROL

Date: Sept 13, 1994

SEP 13 1994

124176

In response refer to File Number F94-34943

This is in response to your request dated Aug 30 1994, in which you requested THE APPROVAL LETTER AND LABELING FOR MEVACOR TABLETS WHICH WAS APPROVED ON MAY 17, 1994.

Your request was received in the Center for Drug Evaluation and Research on Sept 3, 1994.

Enclosed are the documents you requested.

- A search of the records of the Center for Drug Evaluation and Research did not locate any disclosable documents responsive to your request.
- did not locate any documents responsive to your request.
- did not locate an approved New Drug Application nor an approved Abbreviated New Drug Application for this/these product/products.
- found that final printed labeling is not yet available.

Summary Basis of Approval (SBA) are no longer being prepared.

Due to severe resource restrictions, these documents are only available on microfiche. Paper copy cannot be provided. You may wish to view the document at your local library or request a local company provide paper copies from the fiche.

The minutes of the meeting/meetings you requested are still in preparation and are not yet available.

The document you requested is available from the National Technical Information Service, 5285 Port Royal Road, Springfield, Virginia 22161, 703-487-4650.

The portion of your request regarding \_\_\_\_\_ has been referred to the Agency's Freedom of Information Staff Office (HFI-35). They can be reached at 301-443-6310, ext 273.

In order to reduce processing time and costs, certain material may have been deleted from the record(s) furnished to you, because a preliminary review indicated that the deleted material is not required to be publicly disclosed. If, however, you wish to review any deleted material, identify the specific deletion and submit an additional request for this information.

This concludes your request.

You can expect a further response from \_\_\_\_\_.

The following charges will be included in a monthly invoice:

Reproduction \$ \_\_\_\_\_ Search \$ 6.50 Review \$ 6.50 Other \_\_\_\_\_

Total \$ \_\_\_\_\_ DO NOT SEND PAYMENT UNTIL YOU RECEIVE AN INVOICE

If there are any problems with this response, please notify us in writing of your specific problem(s). Please reference the above file number. Thank you for your request.

Sincerely yours,

Seymour Fishman  
Freedom of Information Officer  
Center for Drug Evaluation  
and Research, HFD-19

# foi

**FOI Services, Inc.**  
12315 Wilkins Avenue  
Rockville MD 20852-1877 USA  
Phone: 301/881-0410  
Fax: 301/881-0415

FOOD & DRUG ADMINISTRATION  
FREEDOM OF INFORMATION STAFF  
5600 FISHERS LANE  
ROCKVILLE, MD 20857

8/30/94

CONTROL NUMBER 124176


PURSUANT TO THE PROVISIONS OF THE FREEDOM OF INFORMATION ACT, PLEASE PROVIDE US WITH A PAPER COPY (NOT MICROFICHE) OF THE FOLLOWING DOCUMENTS. IF THE COST OF PROVIDING THESE DOCUMENTS WILL EXCEED 100.00, PLEASE CALL US FIRST FOR AUTHORIZATION OF THE CHARGES, UNLESS INDICATED OTHERWISE BELOW.

PLEASE REFER TO OUR CONTROL NUMBER IN YOUR REPLY.

ATTENTION: CENTER FOR DRUGS

COPY OF ALL DISCLOSABLE APPROVAL INFORMATION, INCLUDING APPROVAL LETTER AND LABELING FOR THE LABELING REVISION APPROVED 5/17/94 FOR MEVACOR TABLETS 10MG, 20MG & 40MG MANUFACTURED BY MERCK.

94-34943



NDA 19-643/S-032  
NDA 19-643/S-033✓

MAY 17 1994

Merck & Co., Inc.  
Attention: Robert E. Silverman, M.D., Ph.D.  
Director, Regulatory Affairs  
BLA-30  
West Point, PA 19486

Dear Dr. Silverman:

Please refer to your March 1 (Supplement-032) and August 19, 1993, (Supplement-033) supplemental new drug applications submitted under section 505(b) of the Federal Food, Drug, and Cosmetic Act for Mevacor (lovastatin) Tablets.

The supplemental applications provide for changes to the package insert regarding the following: Supplement-032 - Deletion of A.H.F.S. categories, editorial revisions to the "Clinical Studies" subsection of the CLINICAL PHARMACOLOGY section, additions to the "Hypersensitivity Reaction" and "Skin" subsections of the ADVERSE REACTIONS section, and class labeling revisions; and Supplement-033 - Revisions to the INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION sections based on the revised National Cholesterol Education Program (NCEP) Guidelines dated June 15, 1993, and includes the changes submitted in Supplement-032.

We have completed our review of these supplemental applications and have concluded that adequate information has been presented to demonstrate that the drug product is safe and effective for use as recommended in the July 1993, final printed labeling submitted in Supplement-033 on August 19, 1993. Accordingly, the supplemental applications are approved effective on the date of this letter.

Should additional information relating to the safety and effectiveness of the drug become available, revision of that labeling may be required.

We remind you that you must comply with the requirements for an approved NDA set forth under 21 CFR 314.80 and 314.81.

Should you have any questions, please contact:

Mr. Stephen T. Trostle  
Consumer Safety Officer  
Telephone: 301-443-3520.

Sincerely yours,

Solomon Sobel, M.D.  
Director  
Division of Metabolism and  
Endocrine Drug Products (HFD-510)  
Center for Drug Evaluation and Research

cc:

Original NDA  
HF-2 (with labeling)  
HFC-130/JAllen  
HFD-80 (with labeling)  
HFD-240 (with labeling)  
HFD-600 (with labeling)  
HFD-730 (with labeling)  
HFD-500/LRipper (with labeling)  
HFD-510  
HFD-510/SAurecchia/CNiu/EBarbehenn  
HFD-510/STrostle/05/12/94/ft/stt/05/16/94 \N19643AP.032  
Concurrence: EGalliers, SAurecchia 05.12; GTroendle, MRhee,  
YChiu, AJordan for EBarbehenn, AJordan 05.16.94

**SUPPLEMENT(S) APPROVAL (AP-032/AP-033)**

Request letter dated 6/7/12/93. No <sup>9</sup> notable differences.

Robert E. Silverman, M.D., Ph.D.  
Director  
Regulatory Affairs

Three copies

not desk copies.

ST 05/12/94  
Merck & Co., Inc.  
BLA-30  
West Point PA 19486  
Fax 215 397 2335  
Tel 215 397 2944  
215 652 5000

REVISION	NDA NO. <u>19643</u>	REF. NO. <u>033</u>
	NDA SUPPL FOR <u>SKR</u>	
DATE		

August 19, 1993

DATE




**MERCK**  
Research Laboratories

Solomon Sobel, M.D. - Director  
Division of Metabolism and Endocrine  
Drug Products HFD-510, Room 14B-04  
Office of Drug Evaluation II (CDER)  
Food and Drug Administration  
5600 Fishers Lane  
Rockville, Maryland 20857

noted  
y/Chen  
8/26/93

noted  
but we still need  
to put the new  
changes into labeling  
EKB  
8/30/93



noted  
MPL 8/24/93

Dear Dr. Sobel:

**SPECIAL SUPPLEMENT - CHANGES BEING EFFECTED**

**NDA 19-643: MEVACOR (Lovastatin)**

Pursuant to Section 505(b) of the Food Drug and Cosmetic Act and in accordance with 21 CFR 314.50(c), we submit, for your approval, a supplement to NDA 19-643.

As indicated on the attached Form FDA 356h, the supplemental application provides for changes in Item 4.c.ii of the approved New Drug Application for Mevacor.

Reference is made to our letter dated June 7, 1993 and your letter dated July 14, 1993 concerning incorporation of the new NCEP Guidelines into the approved labeling for Mevacor.

This supplement is being submitted in response to your July 14, 1993 letter and contains a summary of revisions, an annotated revised package circular, and twelve (12) copies of the final printed package circular (No. 7526525). The labeling has been revised under INDICATIONS AND USAGE and DOSAGE AND ADMINISTRATION based on new NCEP Guidelines dated June 15, 1993.

The changes will become effective on or about October 1, 1993 and will apply to all packages of Mevacor distributed from the company's manufacturing facilities at West Point, Pennsylvania.

8/23/93  
A. Murali

# Explore Litigation Insights

Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

## Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time alerts** and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

## Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

## Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

## API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

## LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

## FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

## E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.